Top Health-care stocks:
Health-care shares were generally unchanged in pre-market trade Tuesday.
In health-care stocks news, Catalyst Pharmaceutical Partners ( CPRX ) a biopharmaceutical company focused on developing and commercializing therapies for people with rare debilitating diseases, announced Tuesday a clinical trial with Firdapse (amifampridine phosphate) in pediatric patients with congenital myasthenic syndromes ( CMS ).
Shares in the company were unchanged at $2.99 pre-bell. Over the past 52 weeks, the company has traded between $2.26 and $5.80.
Infinity Pharmaceuticals ( INFI ) said it expects topline data from its phase 2 trial of duvelisib to treat indolent non-Hodgkin lymphoma by Q3 of 2016 and expects to submit regulatory filings by the end of 2016.
Shares in the company were also unchanged at $8.83 pre-bell. Over the past 52 weeks, the company has traded between $7.56 and $18.25.
And Fate Therapeutics ( FATE ) shares were initiated by Raymond James with an outperform rating and $8 price target.
The company was flat pre-bell at $5.80. The company has traded between $3.50 and $8.78 over the past 52 weeks.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.